Introduction
Radiation maculopathy and papillopathy are complications after radiotherapy for intracranial, skull base, and paranasal sinus tumors. Macular edema and serous retinal detachment associated with radiation maculopathy may lead to severe visual loss. Although the natural history of radiation papillopathy may be more favorable than previously assumed, 1 any cases associated with underlying vascular disorders are more likely to be aggressive 2 and there is still no evidence-based treatment for radiation papillopathy. More recently, there have been isolated reports of intravitreal bevacizumab (Avastin ® ; Genentech Inc, San Francisco, CA) for radiation optic neuropathy or maculopathy secondary to plaque radiotherapy. [3] [4] [5] Here, a case of delayed radiation maculopathy and papillopathy secondary to irradiation for maxillary sinus cancer that was successfully treated with intravitreal bevacizumab is reported.
Case report
A 73-year-old male presented with acute decrease in vision in the left eye 6 years after irradiation therapy for maxillary sinus cancer. The patient had a history of irradiation with a dose of 50-55 Gy in 1.8-1.9 Gy fractions to the cancer without invasion into eye and orbit. Treatment was performed with an anterior and lateral pair of 45° wedged beams. The patient had no diabetes mellitus or vascular disease. On presentation, his best-corrected visual acuity was 1.2 OD and 0.4 OS. Ophthalmoscopy was normal in the right eye but showed optic disc swelling with peripapillary hemorrhage, retinal The patient was suspected to have radiation maculopathy and papillopathy in the left eye. Intravitreal bevacizumab (1.25 mg in 0.05 mL) was provided to reduce vascular hyperpermeability and intraretinal neovascularization. Two weeks after the administration, visual acuity improved to 20/20 with resolution of SRD. Two months after administration, a color photograph showed decreased optic disc swelling, hemorrhage, and exudates ( Figure 2A ). OCT demonstrated complete regression of SRD ( Figure 2C ). The corresponding FA revealed markedly reduced macular edema, decreased intraretinal microangiopathy, and vascular leakage ( Figure 2B ). These findings were maintained over 12 months and at the last follow-up ( Figure 3A -C).
Discussion
Radiation-induced retinopathy, maculopathy, and papillopathy are serious complications of head and neck radiotherapy. Takeda et al have suggested that radiation dose and area irradiated are the most important factors in the development of radiation retinopathy. 6 The results in that study showed that 8/14 (57%) eyes that received 50 Gy or more, over 60% or more of the area of the retina, developed severe retinal complications. 6 Parsons et al also indicated that, in the dose range 45-50 Gy, 8/15 (53%) eyes studied developed retinopathy and there was an increased risk of injury among patients who received fractional doses of over 1.9 Gy. 7 Kim et al reported that 63/93 (67.7%) patients who received 70 cobalt Gy equivalents (CGEs) developed papillopathy a median of 1.5 years after irradiation. 1 Demizu et al found that the maximum dose to the optic nerve (.110 GyE 3 ) was significant for the occurrence of radiation-induced optic neuropathy. 8 Taking this into consideration, in this case with a dose of 50-55 Gy in 1.8-1.9 Gy fractions over 50% of the area of the retina, radiation damage to the macula and optic nerve might be mild and the clinical findings might support that view.
Intravitreal bevacizumab has been used in the treatment of age-related macular degeneration, 9 retinal vein occlusion, 10 and diabetic retinopathy 11 as it inhibits the formation of abnormal blood vessels and reduces vascular hyperpermeability from vascular cell damage. Hopewell has noted that radiation injury in the central nervous system is a consequence of vascular rather than neural cell damage. 12 Radiation papillopathy and maculopathy represent disc swelling, peripapillary hemorrhage, hard exudates, intraretinal 
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Intravitreal bevacizumab for radiation maculopathy and papillopathy edema, subretinal fluid, and capillary nonperfusion by a radiation-damaged microvasculature. Thus, intravitreal bevacizumab may be a reasonable choice for radiation papillopathy and maculopathy, although the severe forms may need more aggressive therapy.
Rapid and sustained resolution of radiation maculopathy and papillopathy by intravitreal bevacizumab may be a consequence of prompt reduction of vascular hyperpermeability and prolonged suppression of retinal neovascularization. A recent study has shown that intravitreous ranibizumab (Lucentis ® ; Genentech, San Francisco, CA) can be used for radiation maculopathy. 13 Because ranibizumab is in the form of smaller molecules with rapid wash-out, the drug may need repeated monthly injections and consequently increase the opportunity for adverse events such as endophthalmitis and retinal detachment. In addition, the costs of ranibizumab are much higher than bevacizumab. Therefore, the longer acting and less expensive bevacizumab therapy may be best for the treatment of radiation vasculopathy, although risk-benefit comparisons are still needed.
